Andermarcher Elisabetta, Bossis Guillaume, Farras Rosa, Jariel-Encontre Isabelle, Piechaczyk Marc
Institut de Génétique Moléculaire de Montpellier, IGMM, UMR 5535/IFR 22 CNRS, 1919, route de Mende, 34293 Montpellier Cedex 05, France.
Med Sci (Paris). 2005 Feb;21(2):141-9. doi: 10.1051/medsci/2005212141.
The proteasome is the main intracellular proteolytic machinery. It is involved in all major cellular functions and decisions. It has long been thought that prior ubiquitinylation of almost all of its substrates was necessary for degradation. It has also long been considered that ubiquitinylation and degradation were two uncoupled mechanisms and that the recruitment of ubiquitinylated species was only performed by specialized subunits of the proteasome. The recent literature questions this simplified view. It also suggests that, on the one hand, the fraction of proteins hydrolyzed by the proteasome independently of their ubiquitinylation has largely been underestimated and, on the other hand, that the recognition of ubiquitinylated proteins involves complex addressing systems. Furthermore, it indicates a higher order structuration of the ubiquitin/proteasome pathway, a fraction of the proteasome and of ubiquitinylation enzymes being engaged in supramolecular complexes. Finally, proteasomal degradation is altered in a number of pathological situations. It, thus, constitutes a therapeutic target and the first applications are emerging.
蛋白酶体是细胞内主要的蛋白水解机制。它参与所有主要的细胞功能和决策。长期以来,人们一直认为几乎所有底物在被降解之前都需要先进行泛素化。长期以来,人们还认为泛素化和降解是两种相互独立的机制,并且泛素化底物的募集仅由蛋白酶体的特定亚基完成。最近的文献对这种简化观点提出了质疑。它还表明,一方面,蛋白酶体水解的不依赖泛素化的蛋白质比例在很大程度上被低估了,另一方面,泛素化蛋白质的识别涉及复杂的寻址系统。此外,它表明泛素/蛋白酶体途径存在更高层次的结构,一部分蛋白酶体和泛素化酶参与超分子复合物。最后,蛋白酶体降解在许多病理情况下会发生改变。因此,它构成了一个治疗靶点,并且首批应用正在出现。